What did Mesoblast (ASX:MSB) acquire from the Mayo Clinic?

Mesoblast has secured an exclusive worldwide licence for a Chimeric Antigen Receptor (CAR) technology platform developed by the Mayo Clinic. This platform allows the company to genetically engineer its mesenchymal lineage stromal cells (MSCs) to include CAR constructs.

How did Mesoblast (ASX:MSB) pay for this technology acquisition?

The acquisition was finalised through the issuance of ordinary shares rather than a cash payment. This preservation of capital allows the company to maintain its cash runway while adding a significant intellectual property asset to its portfolio.

Which diseases will the new CAR-MSC platform target?

Mesoblast (ASX:MSB) intends to use the platform to treat complex inflammatory and autoimmune conditions, specifically targeting ulcerative colitis and Crohn’s disease. Additionally, the company plans to develop candidates expressing CD19 to treat B-cell-mediated diseases such as Lupus Nephritis.

Why is the "homing" capability of these cells important for the investment thesis?

Standard MSCs have natural anti-inflammatory properties, but their ability to concentrate specifically at the site of disease can be limited. By adding CAR technology, Mesoblast aims to "supercharge" these cells so they migrate directly to inflamed tissues, potentially increasing clinical efficacy and reducing the required dose.

What are the main bull points for Mesoblast (ASX:MSB) after this news?

The primary bull case is that Mesoblast is evolving its "off-the-shelf" platform from simple cell therapy to advanced genetic engineering, potentially increasing its market cap through higher-value IP.

What are the key risks for investors following this announcement?

The main risk is that these "next-generation" therapies are still in the early stages and face significant regulatory and clinical hurdles before reaching the market. There is also the risk of further dilution if Mesoblast needs to raise additional capital to fund the clinical trials required for these new CAR-MSC candidates.

Mesoblast acquires Mayo Clinic CAR-MSC technology licence

Written by Liezl GambePublished Apr. 15 2026Last Updated Apr. 15 2026

Mesoblast (ASX:MSB) announced that it has acquired an exclusive worldwide licence for a cutting-edge chimeric antigen receptor technology platform.

The acquisition, finalised through the issuance of ordinary shares, focuses on the precision-enhanced augmentation of Mesoblast's proprietary mesenchymal lineage stromal cell products.

Developed by researchers at the prestigious Mayo Clinic, the platform allows for the genetic engineering of CAR constructs into MSCs, a breakthrough designed to dramatically improve the cells' ability to home in on inflamed tissues.

By increasing target specificity, Mesoblast aims to unlock new levels of potency for treating complex inflammatory and autoimmune conditions, including ulcerative colitis and Crohn’s disease.

The integration of CAR technology represents a pivotal evolution for Mesoblast’s "off-the-shelf" cellular medicines.

Beyond gastrointestinal applications, the company plans to deploy CAR-MSC candidates expressing CD19 to target B-cell-driven autoimmune diseases like lupus nephritis.

CEO Silviu Itescu emphasised that this technology aligns perfectly with the company’s strategy to extend market leadership through superior efficacy and expanded indications.

Under the terms of the agreement, the Mayo Clinic will provide ongoing in-kind support, including GMP manufacturing assistance, to accelerate the development of these next-generation therapies.

At the time of reporting, Mesoblast's share price was $2.07.